This article only represents the author's own views.
Chinese drug maker CStone Pharmaceuticals (2616.HK) is having to swallow a bitter pill after being dropped from a system that gives mainland investors access to Hong Kong stocks.
The reaction was swift and painful after the company lost its status as a Hang Seng index component and was therefore ejected from the Stock Connect list. After the news broke, the share was hit by waves of selling and ended last week down 39.2%.
您已閱讀8%（476字），剩餘92%（5348字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。